If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Acepromazine † — although it is mostly used in veterinary medicine. Chlorpromazine (Thorazine) Cyamemazine † Dixyrazine † Fluphenazine Levomepromazine‡ Mesoridazine (discontinued)† Perazine Pericyazine‡ Perphenazine Pipotiazine ‡ Prochlorperazine Promazine (discontinued) Promethazine Prothipendyl † Thioproperazine‡ (only English-speaking country it is available in is Canada) Thioridazine (discontinued) Trifluoperazine Triflupromazine (discontinued)†
=== Dietary therapy === Initial attempts at dietary therapy in ALD involved restricting the intake of very-long chain fatty acids (VLCFA). Dietary intake is not the only source for VLCFA in the body, as they are also synthesized endogenously. This dietary restriction did not impact the levels of VLCFA in plasma and other body tissues. After the realization that endogenous synthesis was an important contribution to VLCFA in the body, efforts at dietary therapy shifted to inhibiting these synthetic pathways in the body. The parents of Lorenzo Odone, a boy with ALD, spearheaded efforts to develop a dietary treatment to slow the progression of the disease. They developed a mixture of unsaturated fatty acids (glycerol trioleate and glyceryl trierucate in a 4:1 ratio), known as Lorenzo's oil that inhibits elongation of saturated fatty acids in the body. Supplementation with Lorenzo's oil has been found to normalize the VLCFA concentrations in the body, although its effectiveness at treating the cerebral manifestations of the disease is still controversial and unproven. Trials with Lorenzo's oil have shown that it does not stop the neurological degradation in symptomatic patients, nor does it improve adrenal function, but asymptomatic patients, and speculatively AMN variants without cerebral involvement, as well as female carriers may benefit from early intake of oleic and erucic acids in addition to VLCFA restriction.
Cost estimates for the Golden Dome program range from $175 billion (White House), to $1.2 trillion (Congressional Budget Office), to $3.6 trillion (American Enterprise Institute) depending on the architectural details. The wide range largely hinges on the number of space-based missiles and the cost of replacing satellites whose low orbits decay quickly due to atmospheric drag. Some $24.4 billion in federal funding was directed to the Golden Dome in the One Big Beautiful Bill Act in 2025, with another $13 billion allocated for the fiscal year 2026, totaling 2.2% of the federal discretionary budget during that year.
Sources: en.wikipedia.org
Shortly before the Napoleonic Wars, the French government offered a hefty cash award of 12,000 francs to any inventor who could devise a cheap and effective method of preserving large amounts of food to create well-preserved military rations for the Grande Armée. The larger armies of the period required increased and regular supplies of quality food. Limited food availability was among the factors limiting military campaigns to the summer and autumn months. In 1809, Nicolas Appert, a French confectioner and brewer, observed that food cooked inside a jar did not spoil unless the seals leaked, and developed a method of sealing food in glass jars. Appert was awarded the prize in 1810 by Count Montelivert, a French minister of the interior. The reason for lack of spoilage was unknown at the time, since it would be another 50 years before Louis Pasteur demonstrated the role of microbes in food spoilage and developed pasteurization. The Grande Armée began experimenting with issuing canned foods to its soldiers, but the slow process of canning and the even slower development and transport stages prevented the army from shipping large amounts across the French Empire, and the wars ended before the process was perfected. Following the end of the Napoleonic Wars, the canning process was gradually employed in other European countries and the United States.
From October 2010 to May 2011, the Brigade armed essentially Brigade La Fayette in Afghanistan by projecting a headquarter staff ( composed 50% of Marines, Bigors, Marine sapeurs of the 9e BIMa) and the tactical interam groupment of Richelieu armed by the 2nd Marine Infantry Regiment 2e RIMa. In January 2013, elements of the Brigade took part in Operation Serval. In all combat engagement theatres around the globe, the 9e BIMa illustrated worth of the oldest traditions of the French Troop de Marine.
=== Weight harnesses === When large amounts of weight are needed, a harness may be used to carry the load on the diver's shoulders, rather than around the waist, where it may tend to slip down into an uncomfortable position if the diver is working in a vertical posture, which is often the case. Sometimes this is a separate harness, worn under the safety harness, with pockets at the sides to carry the weights, and sometimes it is an integrated system, which carries the weight in pockets built into or externally attached to the safety harness. On the standard diving suit, the load of the weighting system was usually at least partly transferred to the corselet of the copper helmet, to directly counteract the helmet's buoyancy.
== Further reading == Green Analytical Methods and Miniaturized Sample Preparation techniques for Forensic Drug Analysis. 2025. doi:10.1016/C2022-0-02711-2. ISBN 978-0-443-13907-9. Janusz Pawliszyn: Handbook of Solid Phase Microextraction, Chemical Industry Press, 2009. Pawliszyn J.: Solid Phase Microextraction: Theory and Practice, Wiley-VCH, 1997. Pawliszyn J.: Applications of Solid Phase Microextraction, Royal Society of Chemistry, 1999.
Sources: en.wikipedia.org
Some residents warned that, if the situation continued for another week or two, it could lead to a humanitarian crisis, and also expressed concern that the districts might fall to Pakistani forces. Since the closure of roads, Taliban have been airlifting essential supplies to effected areas. Locals in Nuristan also said that the road between Kunar and Nuristan had been closed, and that Pakistani soldiers targeted anyone travelling along the route. Residents of Kunar and Nuristan state that while artillery attacks had occurred in the area for years, road closures and airstrikes had been relatively rare in the past. Meanwhile, an Afghan media outlet, citing a Pakistani official, reported that Pakistani security forces had taken control of several strategic border posts. The official said the positions had been secured because of their tactical importance and elevation, and stated that Pakistan's aim was not to seize Afghan territory but to prevent cross-border infiltration and protect vulnerable areas inside Pakistan. Enayatullah Toofan, a member of Taliban's High Council for Armed Forces Coordination, states that Pakistani forces have occupied parts of Paktika province and issued Pakistani identity cards to the residents there. According to him, Pakistan wants to open girls schools in those areas. However, Enayatullah Khwarizmi, a spokesperson for the Afghan Ministry of Defense, said that all areas on the Afghan side of the border remained under Afghan control and that the Afghan armed forces were committed to defending every inch of the country's territory.
== Occurrence and causes == Chronic kidney disease is one of the most common causes of death in older domestic cats. In many animals, however, the disease initially remains unrecognized, as clinical symptoms are often absent in the early stages of chronic kidney disease due to the kidney's reserve capacity and sufficiently sensitive diagnostic tests are not available for routine use. The data on the frequency of the disease in cats is contradictory, varying between 1.6 and 20%. Chronic kidney disease occurs more frequently in older cats: Over 50% of affected cats are seven years old or older and 30% of all cats over 9 years of age show elevated blood levels of nitrogen compounds (azotemia). However, the disease can occur as early as 9 months of age. Disposition predisposition has been proven for Maine Coon, Abyssinian, Siamese, Russian Blue and Burmese. Since the kidneys have a high reserve capacity and clinical symptoms only appear when two thirds of the original kidney function has been lost, the triggering factors must damage both kidneys. Chronic kidney disease in cats is an idiopathic tubulointerstitial nephritis, i.e. an inflammation of the renal tubules and the renal interstitial tissue without an identifiable cause. In addition to the damage that this primary disease causes directly to the kidney tissue, activated endogenous repair mechanisms such as connective tissue formation lead to further, partially self-sustaining destruction of functional kidney tissue.
== Structural changes == disulfide bridges, the covalent linkage of two cysteine amino acids lysine-cysteine bridges, the covalent linkage of 1 lysine and 1 or 2 cysteine residues via an oxygen atom (NOS and SONOS bridges) proteolytic cleavage, cleavage of a protein at a peptide bond isoaspartate formation, via the cyclisation of asparagine or aspartic acid amino-acid residues racemization of serine by protein-serine epimerase of alanine in dermorphin, a frog opioid peptide of methionine in deltorphin, also a frog opioid peptide protein splicing, self-catalytic removal of inteins analogous to mRNA processing
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.